Shionogi to buy IntraBio for USD 2 billion

Bitget2026/10/05 12:05

Shionogi agreed to buy IntraBio for an upfront USD 2 billion, adding rare-disease drug AQNEURSA to its portfolio. IntraBio would become a wholly owned unit of Shionogi’s U.S. subsidiary upon closing, targeted for November–December 2026. AQNEURSA won U.S. approval in 2024 for neurological manifestations of Niemann-Pick disease type C. The FDA cleared AQNEURSA on Sept. 18, 2026 for ataxia in Ataxia-Telangiectasia, making it the only approved treatment. Deal adds global rights to AQNEURSA and broadens Shionogi’s rare-disease push following its April 2026 acquisition of RADICAVA rights. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050800BIZWIRE_USPR_____20261005_BW854293) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27

Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch

Cryptopotato•2026/10/11 10:21

Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?

BeInCrypto•2026/10/11 10:06

Exclusive Report - Sources Say INWIT Investors Are Raising Funds for a Possible Privatization Deal

路透社•2026/10/11 08:51